Cargando…

Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study

BACKGROUND/AIMS: Crohn’s disease is a chronic disorder; therefore, it is essential to investigate long-term safety and efficacy of treatments. This study assessed the safety and effectiveness of adalimumab for up to 3 years in Japanese patients with Crohn’s disease in real-world settings. METHODS: T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hisamatsu, Tadakazu, Suzuki, Yasuo, Kobayashi, Mariko, Hagiwara, Takashi, Kawaberi, Takeshi, Ogata, Haruhiko, Matsui, Toshiyuki, Watanabe, Mamoru, Hibi, Toshifumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association for the Study of Intestinal Diseases 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566837/ https://www.ncbi.nlm.nih.gov/pubmed/33207857 http://dx.doi.org/10.5217/ir.2020.00025

Ejemplares similares

Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study
por: Ogata, Haruhiko, et al.
Publicado: (2021)

Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn’s Disease
por: Ogata, Haruhiko, et al.
Publicado: (2016)

Effects of vedolizumab in Japanese patients with Crohn’s disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses
por: Watanabe, Kenji, et al.
Publicado: (2019)

Development of algorithms for identifying patients with Crohn’s disease in the Japanese health insurance claims database
por: Morikubo, Hiromu, et al.
Publicado: (2021)

Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: results from a large real-world observational study
por: Suzuki, Yasuo, et al.
Publicado: (2021)

Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study
por: Motoya, Satoshi, et al.
Publicado: (2019)

Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study
por: Motoya, Satoshi, et al.
Publicado: (2019)

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
por: Suzuki, Yasuo, et al.
Publicado: (2013)

Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis
por: Suzuki, Yasuo, et al.
Publicado: (2017)

Evidence-based clinical practice guidelines for Crohn’s disease, integrated with formal consensus of experts in Japan
por: Ueno, Fumiaki, et al.
Publicado: (2012)

Ulcerative colitis outcomes research in Japan: protocol for an observational prospective cohort study of YOURS (YOu and Ulcerative colitis: Registry and Social network)
por: Yamazaki, Hajime, et al.
Publicado: (2019)

Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial
por: Hisamatsu, Tadakazu, et al.
Publicado: (2018)

Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis
por: Kobayashi, Taku, et al.
Publicado: (2019)

Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis
por: Naganuma, Makoto, et al.
Publicado: (2021)

First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis
por: Kobayashi, Taku, et al.
Publicado: (2015)

Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn’s disease
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2018)

Significance of measurement of serum trough level and anti‐drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial
por: Nakase, H., et al.
Publicado: (2017)

Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies
por: Takeuchi, Tsutomu, et al.
Publicado: (2023)

Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis
por: Nakagawa, Hidemi, et al.
Publicado: (2019)

Clinical features of chronic enteropathy associated with SLCO2A1 gene: a new entity clinically distinct from Crohn’s disease
por: Umeno, Junji, et al.
Publicado: (2018)

Endoscopic and Pathologic Changes of the Upper Gastrointestinal Tract in Crohn's Disease
por: Sakuraba, Atsushi, et al.
Publicado: (2014)

Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial
por: Hibi, Toshifumi, et al.
Publicado: (2023)

Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
por: Nakagawa, Tomoo, et al.
Publicado: (2019)

Adalimumab in Crohn’s disease
por: Van Assche, Gert, et al.
Publicado: (2007)

Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries
por: Kobayashi, Taku, et al.
Publicado: (2018)

Adalimumab for the treatment of Crohn’s disease
por: Cassinotti, Andrea, et al.
Publicado: (2008)

Impact of inflammatory bowel disease on Japanese patients’ quality of life: results of a patient questionnaire survey
por: Ueno, Fumiaki, et al.
Publicado: (2016)

5-Aminosalicylic acid aggravates colitis mimicking exacerbation of ulcerative colitis
por: Miyoshi, Jun, et al.
Publicado: (2018)

Langerhans Cell Histiocytosis Caused by Adalimumab for Crohn’s Disease: A Case Report
por: KOCHI, Mariko, et al.
Publicado: (2023)

Investigation of a High-Dose pH-Dependent-Release Mesalazine on the Induction of Remission in Active Crohn’s Disease
por: Suzuki, Yasuo, et al.
Publicado: (2016)

Decreased Plasma Histidine Level Predicts Risk of Relapse in Patients with Ulcerative Colitis in Remission
por: Hisamatsu, Tadakazu, et al.
Publicado: (2015)

Long-Term Follow-Up of Targeted Biopsy Yield (LOFTY Study) in Ulcerative Colitis Surveillance Colonoscopy
por: Hata, Keisuke, et al.
Publicado: (2020)

TGR5 signalling inhibits the production of pro-inflammatory cytokines by in vitro differentiated inflammatory and intestinal macrophages in Crohn's disease
por: Yoneno, Kazuaki, et al.
Publicado: (2013)

Post‐marketing analysis for biosimilar CT‐P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan
por: Sagami, Shintaro, et al.
Publicado: (2021)

The 5C Concept and 5S Principles in Inflammatory Bowel Disease Management
por: Hibi, Toshifumi, et al.
Publicado: (2017)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Management of Crohn’s disease in poor responders to adalimumab
por: de Boer, Nanne KH, et al.
Publicado: (2014)

Efficacy of Adalimumab in Korean Patients with Crohn’s Disease
por: Sohn, Il Woong, et al.
Publicado: (2016)

Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management
por: Park, Dong Il, et al.
Publicado: (2018)

Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment
por: Park, Dong Il, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2vr2kijiha1upgaamlu7lp0q98